Gilead stopped a Phase III study of its CD47 antibody magrolimab in patients who have acute myeloid leukemia with TP53 mutations, the company announced Tuesday.
In a press statement, the company said, “Based on an ad hoc analysis, and following review by an independent data monitoring…
Click here to view original post
